Chronic tissue injury with fibrosis, loss of proper tissue architecture and organ dysfunction are characteristic features of many human diseases and major causes of morbidity and mortality worldwide. Currently, treatment of tissue fibrosis is severely limited, and transplantation is often the only effective option for end-stage fibrotic diseases. However, limited donor organ availability and the high cost and morbidity of transplantation underscore the urgent need for more effective therapies.
Secreted transforming growth factor-β (TGF-β) is arguably the major profibrogenic cytokine and a central mediator of fibrosis in multiple organs. The molecular pathways that regulate TGF-β activity and signaling are therefore attractive targets for new antifibrotic treatments. TGF-β is secreted as a latent complex that is present at high concentrations and directly cross-linked to the extracellular matrix, and much of the regulation of TGF-β function in tissues is based on extracellular activation of this latent complex 1, 2 . Two of the three mammalian TGF-β isoforms (TGF-β1 and TGF-β3) can be activated by members of the integrin family that interact with a linear arginine-glycine-aspartic acid (RGD) motif present in an N-terminal fragment of the TGF-β gene product called the latency-associated peptide [3] [4] [5] . Inhibition and blockade of two of these integrins (α v β 6 and α v β 8 ) result in a phenotype similar to all of the developmental effects of loss of TGF-β1 and TGF-β3 (ref. 6) , suggesting that these two integrins are required for most or all important roles of these TGF-β isoforms in development. However, the mechanisms of TGF-β activation that contribute to tissue pathology in adults are less well understood.
We and others have previously shown that TGF-β activation by the α v β 6 integrin has an important role in models of fibrosis in the lungs, biliary tract and kidney 3, [7] [8] [9] . However α v β 6 does not appear to be critical in all models of organ fibrogenesis, as ablation of α v β 6 was not protective in carbon tetrachloride (CCl 4 )-induced liver fibrosis 7 . Crucially, α v β 6 is largely restricted in its expression to a subset of epithelial cells 7, 10, 11 and generates very localized activation of TGF-β that can only be detected by cells in direct contact with the integrinexpressing cell 3 . Moreover, tissue fibrosis in many organs is due to collagen production by myofibroblasts that are often at a substantial distance from any α v β 6 -expressing epithelial cells with implications for therapeutic design. Myofibroblasts express several α v -containing integrins and are contractile cells capable of exerting force on tethered ligands. The recently solved crystal structure of the small latent complex of TGF-β demonstrates that mechanical force generated by the contractile actomyosin cytoskeleton and transmitted by integrins is a common mechanism for activating latent TGF-β 12 . Furthermore, in vitro studies of myofibroblasts have shown that they can use alternative α v -containing integrins to activate TGF-β 13 , and we and others have shown that several integrins that share the α v subunit, including α v β 1 , α v β 3 , α v β 5 , α v β 6 and α v β 8 , can recognize the same RGD peptide motif and, at least in some circumstances, can activate latent TGF-β 3,4, [14] [15] [16] . Together, these data suggest that myofibroblast α v expression may be critical to fibrosis and may be targetable. However, the precise importance in vivo of each of these integrins is undetermined.
The paucity of tools that allow reliable specific inactivation of genes in myofibroblasts in vivo has greatly hindered progress in understanding the underlying biology of fibrotic diseases. In this study, we developed a strategy to inactivate genes in myofibroblasts in multiple organs. Platelet-derived growth factor receptor-β (PDGFR-β) induction is an early feature of myofibroblast activation in a broad range of tissues [17] [18] [19] [20] [21] [22] [23] [24] . We therefore evaluated the efficiency of targeting these cells using Pdgfrb-Cre mice 25 and used this system to investigate the role of α v -containing integrins on myofibroblasts in regulating pathologic fibrosis in multiple solid organs.
In the liver, HSCs (liver-specific pericytes) are believed to give rise to myofibroblasts upon their activation and thus are the major source of the additional extracellular matrix during hepatic fibrogenesis 26, 27 . To date, no effective strategy has been developed to reliably delete genes specifically in HSCs. As PDGFR-β induction is an early feature of activation of HSCs to myofibroblasts [17] [18] [19] [20] [21] , we evaluated the efficiency of targeting HSCs using Pdgfrb-Cre mice. These mice, which express Cre recombinase under the control of a fragment of the gene encoding PDGFR-β, were previously developed to specifically target pericytes 25 . In the uninjured liver, HSCs are found in a perivascular location in close contact with underlying sinusoidal endothelial cells, and they morphologically resemble pericytes in other organs.
RESULTS

Pdgfrb-Cre effectively targets recombination in HSCs
Using mTmG reporter mice (double-fluorescent reporter mice that express membrane-targeted tandem dimer tomato (tdTomato) before Cre-mediated excision and membrane-targeted GFP (mGFP) after excision) 28 and Ai14 reporter mice (single-fluorescent reporter mice that express tdTomato after recombination) 29 , we found that PdgfrbCre induced highly efficient recombination in a distribution appropriate for HSCs both in uninjured control liver and after induction of hepatic fibrosis with repeated administration of CCl 4 (Fig. 1a,b) . To evaluate the specificity of recombination in HSCs, we stained uninjured control livers from Ai14; Pdgfrb-Cre mice for desmin (a well-characterized marker of HSCs), which was expressed in virtually all of the reporter-expressing cells (Fig. 1c and Supplementary  Fig. 1a) . Staining for PDGFR-β confirmed both appropriate reporter expression by Pdgfrb-Cre and also a hitherto unknown expression of PDGFR-β by quiescent HSCs in uninjured liver ( Fig. 1c  and Supplementary Fig. 1a) . As expected, α-smooth muscle actin (α-SMA, a well-characterized marker of myofibroblasts) was seen only in larger blood vessel walls in uninjured liver (Fig. 1c) . In fibrotic liver, almost all of the reporting cells also expressed desmin and PDGFR-β both in fibrous septae and in the surrounding liver parenchyma ( Fig. 1d and Supplementary Fig. 1a) . Furthermore, virtually all of the α-SMA-positive cells observed in fibrotic livers were also reporter positive ( Fig. 1d and Supplementary Fig. 1a) , demonstrating a high degree of recombination in activated liver myofibroblasts. To further assess specificity of Pdgfrb-Cre recombination, we stained uninjured control and fibrotic livers from Ai14; Pdgfrb-Cre mice with antibodies to CD31 (endothelial cells), F4/80 (Kupffer cells), CD3 (T cells) and pancytokeratin (biliary epithelium). No reporter-expressing cells expressed any of these markers (Supplementary Fig. 1b) . As PDGFR-β expression by quiescent HSCs has not previously been reported, we used an alternative strategy to further assess PDGFR-β Fig. 1c) . Furthermore, to evaluate the specificity of reporting in quiescent HSCs, we stained for desmin, which was expressed in virtually all of the reporter-expressing cells ( Supplementary Fig. 1c,d) . Finally, staining with PDGFR-β demonstrated both appropriate reporter expression by the Pdgfrb-BAC-eGFP system and confirmed expression of PDGFR-β by quiescent HSCs (Supplementary Fig. 1c,d ).
To further characterize reporter-expressing cells in Ai14; PdgfrbCre mice, we isolated nonparenchymal cells from uninjured control or fibrotic livers and purified Ai14 (tdTomato)-positive cells by cell sorting. Quantitative PCR (qPCR) of mRNA obtained from live tdTomatopositive cells showed marked induction of multiple genes associated with the transition of quiescent HSCs to the activated myofibroblast phenotype, including Des (desmin), Pdgfrb, Acta2 (α-SMA), Col1a1 (collagen I), Col1a3 (collagen III), Mmp2 (matrix metallopeptidase 2), Mmp 9 (matrix metallopeptidase 9), Mmp13 (matrix metallopeptidase 13) and Timp1 (TIMP metallopeptidase inhibitor 1) (Fig. 1e) , and higher expression of a number of these mRNAs was also confirmed at the protein level ( Supplementary Fig. 1e-g ). In addition, we found significantly higher expression of multiple β-subunit partners of α v following fibrosis induction (Fig. 1e) . We also plated freshly isolated tdTomato-positive cells from uninjured Ai14; Pdgfrb-Cre mouse livers on tissue culture plastic for 5 d to induce HSC activation. All of the cells in these sorted cultures expressed the myofibroblast marker α-SMA (Fig. 1f) . Taken together, these results suggest that Pdgfrb-Cre efficiently targets both quiescent and activated HSCs.
HSC a v integrin depletion protects mice from hepatic fibrosis To determine whether Pdgfrb-Cre could be used to identify molecular mechanisms driving hepatic fibrosis, we focused on the integrin α v subunit because of the suggested role of various α v -containing integrins in activating latent TGF-β, a central mediator of fibrosis 3,4,13,15,16 .
Confirming our qPCR data ( Fig. 1e) , we found that mouse HSCs express multiple α v -containing integrins (α v β 1 , α v β 3 , α v β 5 and α v β 8 ; Fig. 2a ) and that α v integrin expression was significantly upregulated during activation ex vivo (Fig. 2b,c) . We also found α v integrin expression on hepatic myofibroblasts in human fibrotic liver tissue ( Supplementary Fig. 2a ). Western blotting with an antibody raised against a portion of the α v extracellular domain revealed that α v integrin was efficiently deleted from Itgav flox/flox ; Pdgfrb-Cre HSCs (Fig. 2d) . Furthermore, Itgav flox/flox ; Pdgfrb-Cre mice were significantly protected from CCl 4 -induced fibrosis, as determined by collagen staining, hydroxyproline content and α-SMA staining ( Fig. 2e-h ). This was not due to changes in the degree of initial injury caused by CCl 4 ( Supplementary Fig. 2b,c) , the number of HSCs before injury ( Supplementary Fig. 2d ,e), differences in inflammatory infiltrates ( Supplementary Fig. 2f-i Fig. 3a ). These data suggest that α v integrins on HSCs promote CCl 4 -induced liver fibrosis and that Pdgfrb-Cre effectively targets gene deletion in these cells during fibrogenesis. (Fig. 3a-c) . Furthermore, treatment with an α v -blocking antibody (RMV-7) also inhibited expression of these profibrotic genes ( Fig. 3d-f) . HSCs activated in culture from npg control and Itgav flox/flox ; Pdgfrb-Cre mice had similar Tgfb1 mRNA levels (Fig. 3g) . However, culture of HSCs from control and Itgav flox/flox ; Pdgfrb-Cre mice with mink lung epithelial reporter cells (TMLCs) expressing firefly luciferase under the control of the TGF-β-sensitive plasminogen activator inhibitor-1 promoter 30 demonstrated a significant reduction in the levels of active TGF-β by α v -null HSCs compared to control HSCs. This difference was eliminated by TGF-β-blocking antibody and rescued with addition of activated TGF-β1 (Fig. 3h) , identifying a decrease in TGF-β activation by α v -null HSCs. Furthermore, we found no appreciable difference in levels of total TGF-β1 protein in cell lysates and supernatants from control and Itgav flox/flox ; Pdgfrb-Cre HSCs cultured with and without TMLCs, confirming that the reduction in TGF-β activation by Itgav flox/flox ; Pdgfrb-Cre HSCs is not secondary to a decrease in total TGF-β1 expression ( Supplementary Fig. 3b,c) . Moreover, addition of TGF-β1 to control and Itgav flox/flox ; Pdgfrb-Cre HSCs restored profibrotic gene expression in α v -null HSCs to TGF-β1-treated control levels ( Supplementary Fig. 3d,e) . As multiple cell types can secrete TGF-β, we investigated the cellular sources of TGF-β during liver fibrosis by purifying HSCs, hepatocytes, liver sinusoidal endothelial cells and Kupffer cells from fibrotic livers of C57BL/6 mice and found that the major cellular sources of TGF-β were HSCs and Kupffer cells (Supplementary Fig. 4a ). Previous studies have shown that TGF-β activation occurs in a highly spatially restricted manner 3 but that integrins can activate TGF-β produced by any cells in the local vicinity. We also examined whether adhesion and migration defects in α v -null HSCs might contribute to the protection from CCl 4 -induced fibrosis observed in Itgav flox/flox ; Pdgfrb-Cre mice. However, there was no appreciable difference in adhesion to multiple matrix proteins present in normal or fibrotic liver and no difference in cell migration between control and Itgav flox/flox ; Pdgfrb-Cre HSCs ( Supplementary  Fig. 4b,c) . Furthermore the rate of apoptosis (assessed by TUNEL staining) was similar in control and Itgav flox/flox ; Pdgfrb-Cre HSCs (Supplementary Fig. 4d,e) . We also assessed whether depletion of the α v integrin on HSCs might alter the expression of other β 1 integrin subunit-containing integrins; however, expression of α 1 , α 5 and β 1 integrins was similar in control and Itgav flox/flox ; Pdgfrb-Cre HSCs (Supplementary Fig. 5a-c) .
As we had shown that Itgav flox/flox ; Pdgfrb-Cre HSCs are defective in their ability to activate TGF-β in vitro, we extended our findings in vivo by examining canonical TGF-β signaling by immunostaining for phosphorylated SMAD3 (p-Smad3) (Fig. 3i) . Digital image quantification demonstrated significantly reduced p-Smad3 signaling in the livers of Itgav flox/flox ; Pdgfrb-Cre mice compared to controls following chronic CCl 4 administration (Fig. 3j) . Taken together, these results strongly suggest that the protection from CCl 4 -induced hepatic fibrosis observed in Itgav flox/flox ; Pdgfrb-Cre mice is at least in part a consequence of reduced TGF-β activation by α v -deficient HSCs.
Assessment of a v integrin heterodimers in hepatic fibrosis
The α v integrin subunit has five possible β-subunit binding partners (β 1 , β 3 , β 5 , β 6 and β 8 ) 31 , each of which has been reported to bind and/or activate latent TGF-β 3,4,14-16 and four of which we found were expressed on HSCs (α v β 1 , α v β 3 , α v β 5 and α v β 8 , Fig. 2a) .
To further assess the potential contribution of each α v integrin heterodimer during hepatic fibrogenesis, we evaluated the response to CCl 4 in mice globally lacking β 3 , β 5 and β 6 integrins (previously been shown to be important in biliary tract fibrosis 7 ) and in mice lacking β 8 integrins on HSCs (Itgb8 flox/flox ; Pdgfrb-Cre). We used conditional deletion of Itgb8 from HSCs because global loss of Itgb8 is embryonically lethal 32 . Individual depletion of any one of these β integrin subunits failed to protect mice from CCl 4 -induced hepatic fibrosis (Fig. 4) . These results suggest either that multiple α v -containing integrins contribute to hepatic fibrogenesis and TGF-β activation by HSCs or that the principal relevant integrin is α v β 1 . It is not currently possible to Selective a v integrin depletion in lung and kidney fibrosis Myofibroblasts in the lung and kidney are also the major mediators of extracellular matrix deposition and organ scarring during tissue injury and have previously been shown to express high levels of PDGFR-β [22] [23] [24] 36 . We therefore suspected that Pdgfrb-Cre might broadly mark myofibroblasts in multiple organs and allow manipulation of specific genes in these cells. To further evaluate this possibility, we initially examined the lungs of mTmG; Pdgfrb-Cre reporter mice 28 d after intratracheal instillation of saline (control) or bleomycin. We found high levels of reporter expression in a distribution that closely resembled that of lung pericytes in control saline-treated lungs (Fig. 5a) . We also saw a marked expansion of reporter cells in fibrotic regions following induction of pulmonary fibrosis with bleomycin ( Fig. 5a) . To confirm that reporter expression was occurring specifically in lung pericytes in control saline-treated lung, we stained for desmin and PDGFR-β (two well-characterized markers of pericytes 37 ) and found a high degree of colocalization of the reporter with each ( Fig. 5b and Supplementary Fig. 5d ). Following bleomycin treatment, almost all of the reporter cells expressed desmin and PDGFR-β ( Fig. 5c and Supplementary Fig. 5d ), and most expressed α-SMA ( Fig. 5c and Supplementary Fig. 5d ), demonstrating a high degree of recombination in lung myofibroblasts. We also found marked induction of multiple genes associated with lung fibrogenesis, including Acta2, Col1a1, Co3a1, Mmp2 and Timp1, at both day 14 and day 28 after bleomycin instillation as measured by qPCR of extracts from sorted Ai14-tdTomato-positive cells from control or bleomycin-treated animals (Fig. 5d) . And higher expression of α-SMA protein confirmed myofibroblast induction in sorted Ai14-tdTomato-positive cells following bleomycin treatment (Supplementary Fig. 6a) . Furthermore, all sorted reporter cells (isolated from uninjured Ai14; Pdgfrb-Cre mouse lungs) that were activated in vitro by 7-d culture on tissue culture plastic expressed α-SMA (Supplementary Fig. 6b) . Control or Itgav flox/flox ; Pdgfrb-Cre mice were treated with saline or bleomycin, and lungs were harvested 28 d after instillation. Bleomycin induced the expected fibrosis in control mice (as determined by picrosirius red staining and hydroxyproline content), but Itgav flox/flox ; Pdgfrb-Cre mice were completely protected in this model (Fig. 5e,f) . These data demonstrate a central regulatory role for α v -containing integrins on lung pericytes and/or myofibroblasts during lung fibrogenesis. As stated above, renal myofibroblasts express PDGFR-β and are key effector cells in the deposition of extracellular matrix during renal fibrogenesis 24 . To investigate whether Pdgfrb-Cre efficiently targets renal myofibroblasts, we used the unilateral ureteric obstruction (UUO) model of kidney fibrosis. We performed sham operation or UUO on mTmG; Pdgfrb-Cre reporter mice and harvested left kidneys 14 d after surgery. In sham-operated mice, mGFP-positive reporter cells were perivascular, intraglomerular and within the renal interstitium (Fig. 5g) . UUO resulted in a massive expansion of reporterpositive cells throughout the renal interstitium (Fig. 5g) . As in the liver and lung, qPCR of material from sorted live Ai14-tdTomatopositive cells from Ai14; Pdgfrb-Cre reporter mice showed induction of a panel of genes known to be induced when renal myofibroblasts become activated (Fig. 5h) , and higher expression of α-SMA protein confirmed myofibroblast induction in sorted Ai14-tdTomato-positive cells following UUO (Supplementary Fig. 6c) . Furthermore, freshly isolated Ai14-tdTomato-positive cells (isolated from uninjured Ai14; Pdgfrb-Cre mouse kidneys) cultured on tissue culture plastic for 7 d all expressed the myofibroblast marker α-SMA ( Supplementary  Fig. 6d) . As in the liver and lung fibrosis models above, myofibroblast-specific deletion of Itgav was protective against UUO-induced kidney fibrosis, as determined by picrosirius red staining and digital morphometric analysis (Fig. 5i,j) . Taken together, these data demonstrate that α v -containing integrins on tissue myofibroblasts contribute to pathological tissue fibrosis in multiple solid organs.
We have previously shown an important role for the epithelialexpressed α v β 6 integrin in bleomycin-induced pulmonary fibrosis 3 and UUO-induced kidney fibrosis 8, 9 , and in this study we demonstrate that myofibroblast-expressed α v integrins also contribute to lung and kidney fibrosis. Together, our findings show that both cell lineages play an active part in pulmonary and renal fibrogenesis, further underlining the complex cellular interplay defining the program of tissue fibrosis. To exclude an indirect role of loss of α v on myofibroblasts on α v β 6 expression on adjacent epithelial cells, we assessed α v β 6 expression in control and fibrotic lung, liver and kidney in control and Itgav flox/flox ; Pdgfrb-Cre mice. We found no appreciable difference in α v β 6 integrin expression between control and Itgav flox/flox ; Pdgfrb-Cre mice in uninjured or fibrotic lung, liver and kidney tissue (Supplementary Fig. 6e-j) . These data demonstrate that the protection from fibrosis seen in the Itgav flox/flox ; Pdgfrb-Cre mice is not secondary to altered α v β 6 integrin expression.
Blockade of a v integrins attenuates liver and lung fibrosis Taken together, our data indicate that myofibroblast α v inhibition might represent a valuable therapeutic target. Therefore, we used a previously uncharacterized small-molecule inhibitor of α v integrins, CWHM 12 ( Supplementary Fig. 7a) , to determine whether pharmacological blockade of α v integrins could attenuate fibrosis. CWHM 12 is a synthetic small-molecule RGD peptidomimetic antagonist that consists of a cyclic guanidino-substituted phenyl group as the arginine mimetic and a phenyl-substituted β amino acid as the aspartic acid mimetic, both linked by glycine (a detailed description of the design and synthesis of CWHM 12 is provided in the Online Methods). CWHM 12 demonstrated high potency against all of the five possible β-subunit binding partners (α v β 1 , α v β 3 , α v β 5 , α v β 6 and α v β 8 ) in in vitro ligand-binding assays, with somewhat less potency against α v β 5 than against the other α v integrins ( Supplementary  Fig. 7c-g,k) . We also assessed a control small molecule, CWHM 96, which is the R enantiomer of CWHM 12 and differs only in the orientation of its carboxyl (CO 2 H) group (Supplementary Fig. 7b and Online Methods). In contrast to CWHM 12, CWHM 96 did not inhibit any of the five possible β-subunit binding partners (α v β 1 , α v β 3 , α v β 5 , α v β 6 and α v β 8 ) in in vitro ligand-binding assays ( Supplementary Fig. 7c-g,k) . Furthermore, to assess the specificity of CWHM 12, we analyzed the effect of CWHM 12 in in vitro ligandbinding assays for the non-α v integrins α IIb β 3 , α 2 β 1 and α 10 β 1 . We found that CWHM 12 had no effect on ligand binding for each of these integrins (Supplementary Fig. 7h-j) .
We initially examined the potential of CWHM 12 to prevent liver fibrosis by inserting Alzet osmotic minipumps containing either CWHM 12 or vehicle control into C57BL/6 mice, followed by CCl 4 injections twice weekly for 6 weeks (Fig. 6a) . Treatment with CWHM 12 significantly reduced liver fibrosis, as determined by collagen (picrosirius red) and α-SMA staining and hydroxyproline content (Fig. 6a-d) .
We next asked whether CWHM 12 could prevent further progression of established fibrosis. We treated mice with CCl 4 for 3 weeks to establish fibrotic disease and then with CWHM 12 or vehicle for the final 3 weeks of CCl 4 (Fig. 6e) . CWHM 12 significantly reduced liver fibrosis even after fibrotic disease had been established (Fig. 6e-h ). In addition, we examined canonical TGF-β signaling in the livers of control and CWHM 12-treated mice following chronic CCl 4 administration by immunostaining for p-Smad3 ( Supplementary  Fig. 8a,b) . Digital image quantification demonstrated significantly reduced p-Smad3 signaling in the livers of CWHM 12-treated mice compared to controls (P < 0.01), demonstrating that the protection from CCl 4 -induced hepatic fibrosis observed in CWHM 12-treated mice is due at least in part to a reduction in TGF-β activation by α v integrins (Supplementary Fig. 8a,b) . Furthermore, treatment with CWHM 96 (the control R enantiomer of CWHM 12) had no effect on liver fibrosis, as determined by collagen (picrosirius red) staining and hydroxyproline content (Supplementary Fig. 8c-f) . As α v integrin depletion on myofibroblasts also had antifibrotic effects in the lung (Fig. 5e,f) , we assessed whether CWHM 12 administration beginning 14 d after intratracheal bleomycin could prevent further progression of lung fibrosis (Fig. 6i) . Similar to our findings in the liver, administration of CWHM 12 significantly inhibited progression of pulmonary fibrosis (Fig. 6j) . As we have shown that loss or functional blockade of the epithelial-restricted α v β 6 integrin also prevents pulmonary fibrosis in this model, we cannot be sure that CWHM 12 was not protective in the lung because of its inhibitory effects on α v β 6 . Nonetheless, our findings suggest that inhibition of α v integrins by the small molecule CWHM 12 has potential clinical utility in the treatment of patients with a broad range of fibrotic diseases.
DISCUSSION
Myofibroblasts are a major source of extracellular matrix that accumulates during fibrosis 36 . However, the paucity of tools for reliable inactivation of genes in myofibroblasts in vivo has greatly impeded progress in dissecting the molecular mechanisms driving organ fibrosis, thereby slowing the discovery of new mechanistically targeted antifibrotic treatments. In this study, we developed a system (Pdgfrb-Cre) to genetically manipulate myofibroblasts in multiple organs. Using this system, we identified a key role for myofibroblast α v integrins in the regulation of fibrosis and then validated our approach by using a small molecule to target α v integrins. We have thus identified a targeted approach to treat fibrosis. As a first test of the effectiveness of this system, we deleted the α v integrin subunit from myofibroblasts and found that such depletion markedly inhibited fibrosis in the liver, lung and kidney, identifying myofibroblast α v -containing integrins as components of a core pathway widely shared by pathological fibrosis in multiple solid organs. Of note, we were unable to effectively inhibit liver fibrosis by individual depletion of four of the β-subunit partners of α v (β 3 , β 5 , β 6 or β 8 ), suggesting either that this protection was due to loss of α v β 1 (which cannot be studied with the tools currently available) or, more likely, that inhibition of multiple α v -containing integrins is required to effectively treat liver fibrosis. Using a small-molecule inhibitor, CWHM 12, we showed that therapeutically targeting all α v -containing integrins effectively treated fibrosis in multiple organs. Notably, a recent study using cilengitide (an antagonist selective for mainly α v β 3 and α v β 5 with less potency toward α v β 6 ) demonstrated a 30% increase in hepatic collagen in two models of liver fibrosis 38 , supporting the idea that blockade of all α v -containing integrins may be required to obtain substantial antifibrotic effects. Furthermore, inhibition of TGF-β1 signaling through pharmacological blockade of α v -containing integrins with a small molecule such as CWHM 12 may yield the desired antifibrotic effects without the unwanted potential side effects of pan-TGF-β blockade (autoimmunity and carcinogenesis). However, comprehensive toxicology testing with CWHM 12 will be required before consideration of clinical trials.
As discussed above, one potential mechanism of protection for eliminating or blocking α v -containing integrins is inhibition of activation of TGF-β. Our findings that loss of α v led to a reduction in in vivo p-Smad3 immunostaining, expression of TGF-β-inducible genes and TGF-β activation in culture by HSCs supports a role for this mechanism. TGF-β is a major profibrogenic cytokine and a central mediator of fibrosis in many tissues [39] [40] [41] . However, our results do not exclude other functions of α v integrins on myofibroblasts in contributing to tissue fibrosis.
It is of interest that activation of TGF-β appears to be a common function of multiple α v -containing integrins. Many of the functional roles for distinct β-subunit partners of α v are clearly unique, as demonstrated by the markedly different phenotypes described by us and others for mice globally lacking β 3 , β 5 , β 6 and β 8 . Because of the absence of useful reagents to specifically examine the roles of α v β 1 in vivo, it remains possible that α v β 1 could be the major integrin responsible for TGF-β activation by myofibroblasts, but previously published in vitro npg
